Tiffany Lin

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

Michael Jeffers, Heikki Joensuu, Tim Eisen, 2012, The Lancet. Oncology.